Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-25 00:00 |
Q1 Mitteilung / Q1 Finanzbericht 2023/2024
|
German | 180.9 KB | ||
| 2024-04-17 09:24 |
Heidelberg Pharma AG: Walter Miller, buy
|
English | 8.1 KB | ||
| 2024-04-09 00:00 |
Jahresabschluss zum Geschäftsjahr vom 01.12.2022 bis zum 30.11.2023
|
German | 2.3 MB | ||
| 2024-04-05 09:30 |
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
|
English | 12.8 KB | ||
| 2024-03-27 09:01 |
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary AT…
|
English | 12.8 KB | ||
| 2024-03-26 16:11 |
Heidelberg Pharma AG: Dr. Georg F. Baur, buy
|
English | 9.0 KB | ||
| 2024-03-26 00:00 |
Annual financial report 2022/2023
|
English | 5.7 MB | ||
| 2024-03-25 07:10 |
Heidelberg Pharma announces financial figures and reports on successful busines…
|
English | 35.1 KB | ||
| 2024-03-19 09:47 |
Heidelberg Pharma announces receipt of non-refundable upfront cash payment foll…
|
English | 11.5 KB | ||
| 2024-03-18 07:25 |
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC ca…
|
English | 13.3 KB | ||
| 2024-03-06 07:46 |
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Propr…
|
English | 17.6 KB | ||
| 2024-03-04 11:19 |
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty…
|
English | 14.8 KB | ||
| 2024-03-04 11:02 |
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty…
|
English | 13.1 KB | ||
| 2024-01-31 17:45 |
Heidelberg Pharma AG: Walter Miller, Annahme der Gewahrung von 60.000 Aktienopt…
|
German | 8.3 KB | ||
| 2024-01-31 17:38 |
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Annahme der Gewahrung von 60.000 …
|
German | 8.3 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
